(Press-News.org) BOSTON—Most patients with thyroid eye disease treated with teprotumumab didn’t require additional treatments nearly 2 years later, according to industry-supported research being presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass., and published in the journal Thyroid.
“Thyroid eye disease is a lifelong autoimmune disease that can worsen or flare, regardless of how it has been treated. This is the case for many autoimmune diseases,” said George Kahaly, M.D., Ph.D., professor of medicine and endocrinology at Johannes Gutenberg University Medical Center in Mainz, Germany. “Given the enduring nature of thyroid eye disease, it is important to understand whether patients who are treated with a full course of teprotumumab (eight infusions) can expect to experience lasting improvements in signs and symptoms, like eye bulging and double vision.”
Due to the longevity of thyroid eye disease, Kahaly added, it was important to look at longer-term results after treating patients with teprotumumab. Kahaly and colleagues sought to answer whether or not patients with thyroid eye disease would see sustained improvements in eye bulging (proptosis) and double vision (diplopia).
The study was sponsored by Amgen, which manufactures teprotumumab.
The researchers analyzed pooled clinical trial data beyond the 24-week treatment period for patients in phase 2, OPTIC, and OPTIC-X studies who received a full course of teprotumumab, up to week 72 (51 weeks post-final teprotumumab infusion). They also investigated whether or not patients received additional therapy from week 24 through week 120 (99 weeks post-therapy) as a measure of persistent benefit.
The data revealed patients who received teprotumumab mostly maintained efficacy 51 weeks after the final infusion at week 72.
Nearly two years after the treatment period was complete, 82% of patients did not need further treatment for thyroid eye disease. Of the 106 reporting patients, 18% (19/106) received additional medication, either systemic steroids or teprotumumab, and/or remedial periocular surgery as of 99 weeks post-therapy.
“As physicians consider treatment approaches for their thyroid eye disease patients, they now have longer-term data to support the use of teprotumumab in appropriate patients,” Kahaly said.
# # #
About the Endocrine Society
Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.
The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org. Follow us on Twitter at @TheEndoSociety and @EndoMedia.
About the American Thyroid Association®
The American Thyroid Association® (ATA) is dedicated to transforming thyroid care through clinical excellence, education, scientific discovery and advocacy in a collaborative and diverse community. ATA® is an international professional medical society with over 1,800 members from 43 countries around the world. The ATA® promotes thyroid awareness and information through Clinical Thyroidology® for the Public, a resource that summarizes research for patients and families, and extensive, authoritative resources on thyroid disease and thyroid cancer in both English and Spanish. The ATA® website www.thyroid.org serves as a bona fide clinical resource for patients and the public who look for reliable thyroid-related information.
About the Publisher
Mary Ann Liebert, Inc. is a global media company dedicated to creating, curating, and delivering impactful peer-reviewed research and authoritative content services to advance the fields of biotechnology and the life sciences, specialized clinical medicine, and public health and policy. For complete information, please visit the Mary Ann Liebert, Inc. website.
END
BOSTON—Older women with low bone density are more likely to experience their first hip fracture in their 60s compared to older ages, according to research being presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
“Older women experience an increased risk of fragility hip fractures. These are hip fractures with minimal trauma or due to a fall from a standing height, and they are often deadly and disabling,” said Avica Atri, M.D., an Internal Medicine resident physician at Jefferson Einstein Hospital in Philadelphia, Pa. “As the population over 60 swells in the United States, a large proportion of women will be ...
In an impressive leap forward for robotics technology, researchers from Shanghai Jiao Tong University have unveiled a novel hybrid-driven origami gripper, designed to tackle the challenge of grasping and manipulating objects with unprecedented versatility and precision. This innovative device, highlighted in a recent study published in Cyborg Bionic Systems, promises to reshape the capabilities of robotic systems in industries ranging from manufacturing to healthcare.
The newly developed gripper utilizes a combination of pneumatic and cable-driven mechanisms to control an origami-inspired structure, allowing for adjustable finger stiffness and variable finger lengths. This sophisticated ...
In an era marked by rapid technological advancement in biomedical engineering, a groundbreaking development is set to revolutionize our approach to drug testing and disease modeling. Researchers from Shanghai University and the University of California Los Angeles have made significant strides in the field of in vitro vascularized organ-on-a-chip systems, offering a promising alternative to traditional methods that rely heavily on animal testing and simplistic two-dimensional cell cultures.
The organ-on-a-chip technology mimics human organs on a microscale by cultivating cells in a controlled microenvironment that simulates the 3D structure and physiological ...
BOSTON—A novel male contraceptive gel combining two hormones, segesterone acetate (named Nestorone) and testosterone, suppresses sperm production faster than similar experimental hormone-based methods for male birth control, according to a new study.
Results from an ongoing multicenter phase 2b clinical trial will be presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston.
“The development of a safe, highly effective and reliably reversible contraceptive method for ...
BOSTON—Men who illicitly used steroids to boost muscle size and physical performance and have stopped in the past year have impaired sexual function compared with men currently using steroids, according to a study being presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Having a psychiatric diagnosis and stopping steroids was associated with greater impairment in sexual function, the researchers found.
“It is important to recognize the symptoms that men experience within the first year of stopping ...
BOSTON—Women experiencing moderate-to-severe vasomotor symptoms face a three times greater risk for metabolic-dysfunction-associated steatotic liver disease (MASLD) compared to those with mild symptom severity, according to research being presented Monday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Vasomotor symptoms include hot flashes or night sweats—symptoms that have become synonymous with menopause.
“This research is significant as it contributes ...
The world of robotics is witnessing a transformative shift with the rise of soft robotics, which offers unparalleled flexibility and adaptability in various applications, from medical interventions to intricate rescue operations. A groundbreaking review article by Zhou et al. published in Cyborg Bionic Systems in 2024, sheds light on this evolution, highlighting the crucial integration of actuation and sensing technologies that pave the way for truly intelligent soft robots.
Soft robots, unlike their rigid counterparts, are made from materials that mimic the mechanical properties of living tissues, allowing them to move and adapt with a life-like grace. This capability makes ...
BOSTON—Almost one out of five breast cancer survivors may experience weight gain of more than 10%, suggests a study presented Monday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass. A number of factors are associated with excessive weight gain, the researchers found.
Factors associated with more than 10% weight gain included a lower weight, younger age, and more advanced cancer stage at cancer diagnosis; hormone-positive breast cancer; mutations of the BRCA2 gene; undergoing more aggressive breast surgery; and the use of chemotherapy and endocrine therapy, the study found.
“Weight ...
An immunotherapy drug given before surgery instead of chemotherapy meant that over ten times more patients with a certain genetic profile were cancer free after surgery, according to clinical trial results presented by researchers at UCL and UCLH.
The findings, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024, are interim results from the NEOPRISM-CRC phase II clinical trial assessing whether the immunotherapy drug pembrolizumab can improve outcomes for patients with stage two or stage three MMR deficient/MSI-High bowel cancer. The ...
About The Study: A stepped-care model, with palliative care visits occurring only at key points in patients’ cancer trajectories and using a decrement in quality of life to trigger more intensive palliative care exposure, resulted in fewer palliative care visits without diminishing the benefits for patients’ quality of life. While stepped palliative care was associated with fewer days in hospice, it is a more scalable way to deliver early palliative care to enhance patient-reported outcomes.
Quote from corresponding author Jennifer S. Temel, M.D.:
“This study demonstrates that early palliative ...
